Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4 [0.03%]
MYC通过FTH1和GPX4抑制铁死亡从而诱导结直肠癌顺铂耐药性
Yucheng Wang,Yulan Chen,Che Li et al.
Yucheng Wang et al.
Purpose: Oxaliplatin resistance remains a major obstacle in the treatment of colorectal cancer (CRC). This study aimed to determine whether MYC contributes to oxaliplatin resistance by regulating ferroptosis and to clarif...
Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review [0.03%]
先天性软骨发育不全的化疗和免疫治疗剂量挑战：病例报告和文献回顾
Karolijn W M Groot Beumer,E M J Durlinger,S W J Zielhuis et al.
Karolijn W M Groot Beumer et al.
Introduction: Currently, no established guidelines exist for dosing chemotherapy or immunotherapy in patients with achondroplasia. Case: ...
A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer [0.03%]
DPYD c.812delT罕见变异型导致舌癌患者S-1不良反应事件严重化
Hiroki Ishimura,Atsushi Suehiro,Daiki Hira et al.
Hiroki Ishimura et al.
Dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, plays an important role in the metabolism of fluoropyrimidine (FP) drugs, including tegafur, in S-1. A decrease in DPD activity can cause severe FP-related toxicity. ...
Development of a simplified population pharmacokinetic-pharmacodynamic framework for exposure-informed risk stratification of neutropenia during amrubicin treatment [0.03%]
用于依那西普治疗期间中性粒细胞减少风险分层的简化人群药物代谢动力学-药物效应动力学框架的建立
Yoshinori Makino,Takanori Ogawa,Reiko Makihara-Ando et al.
Yoshinori Makino et al.
Background: Amrubicin is an important chemotherapeutic agent for small cell lung cancer; however, severe neutropenia is a major dose-limiting toxicity. Exposure to its active metabolite, amrubicinol, has been associated w...
Drug repurposing as a promising therapeutic strategy against renal cell carcinoma [0.03%]
药物再定位在肾细胞癌治疗中的前景及其策略
Ali Nakhaei,Atefeh Taghavi,Mahdieh Aliyari et al.
Ali Nakhaei et al.
Renal cell carcinoma (RCC) is a highly vascularized and metastatic malignancy of the kidney. The 5-year overall survival rate of RCC patients remains poor despite the development of therapeutic modalities. Therefore, identifying novel appro...
Red blood cell partitioning and the interpretation of palbociclib plasma concentrations - a letter to the editor [0.03%]
关于palbociclib血浆浓度的解释与红细胞分布——致编辑的信
Julie Sowa,Sophia Chabane,Fanny Bret et al.
Julie Sowa et al.
Zolbetuximab-induced gastric mucosal injury and hypoalbuminemia: a mechanism-informed clinical analysis [0.03%]
佐鲁贝妥昔单抗引起的胃粘膜损伤和低白蛋白血症：基于机制的临床分析
Yoshitomo Yanagimoto,Kazuyoshi Yamamoto,Kei Yamamoto et al.
Yoshitomo Yanagimoto et al.
Purpose: Zolbetuximab plus chemotherapy is standard first-line therapy for HER2-negative, CLDN18.2-positive advanced gastric or gastroesophageal junction cancer (GC/GEJC), but the incidence, course, and clinical correlati...
Correction to: The CetuxIMAX study: a population pharmacokinetic approach to modelling the pharmacokinetics and pharmacodynamics relationships of Cetuximab in patients with head and neck cancer [0.03%]
Correction to: The CetuxIMAX研究：一种用于描述西妥昔单抗在头颈部癌症患者中群体药代动力学及药效关系的建模方法
Clémence Marin,Anthéa Deschamps,Quentin Gerbault et al.
Clémence Marin et al.
Published Erratum
Cancer chemotherapy and pharmacology. 2026 Jul 18;96(1):77. DOI:10.1007/s00280-026-04917-6 2026
The value of target-site physiologically-based pharmacokinetics for high-affinity small molecules: a mechanistic foundation for precision dosing in oncology and hematology [0.03%]
基于生理学的药代动力学模型在高亲和力小分子精准给药中的价值：血液病与肿瘤精准治疗的机制基础
Suzanne van der Gaag,Daniela E Oprea-Lager,André N Vis et al.
Suzanne van der Gaag et al.
For decades, oncology dose selection has been guided by the maximum tolerated dose (MTD) and plasma pharmacokinetics (PK), reflecting assumptions appropriate for classical cytotoxic chemotherapies. However, the advent of high-affinity, targ...
Pharmacologic de-escalation of dexamethasone during weekly paclitaxel: a randomized phase III trial evaluating safety, endocrine effects, and quality of life [0.03%]
地塞米松逐步减量联合每周紫杉醇治疗的III期临床试验：安全性、内分泌作用及生活质量评估
Vanessa Armenio Scontre,Marcos Tadashi Kakitani Toyoshima,Maria Del Pilar Estevez-Diz
Vanessa Armenio Scontre
Objective: Dexamethasone is routinely used as premedication during weekly paclitaxel to prevent hypersensitivity reactions; however, prolonged corticosteroid exposure may induce clinically relevant metabolic, endocrine, a...